In addition to agonists for specific subtypes, pharmacological double PPARα/γ agonists that activate more than one PPAR, called glitazars, have been developed to improve insulin resistance, dyslipidemia,54 and fatty liver55 in rodents. This evidence concerns the gene PPARA and metabolic syndrome.